These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation. Qiu XY; Hu DX; Chen WQ; Chen RQ; Qian SR; Li CY; Li YJ; Xiong XX; Liu D; Pan F; Yu SB; Chen XQ Biochim Biophys Acta Mol Basis Dis; 2018 May; 1864(5 Pt A):1754-1769. PubMed ID: 29510196 [TBL] [Abstract][Full Text] [Related]
23. Current advances in PD-1/PD-L1 axis-related tumour-infiltrating immune cells and therapeutic regimens in glioblastoma. Shu C; Li Q Crit Rev Oncol Hematol; 2020 Jul; 151():102965. PubMed ID: 32442903 [TBL] [Abstract][Full Text] [Related]
24. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885 [TBL] [Abstract][Full Text] [Related]
25. Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy. Cui X; Ma C; Vasudevaraja V; Serrano J; Tong J; Peng Y; Delorenzo M; Shen G; Frenster J; Morales RT; Qian W; Tsirigos A; Chi AS; Jain R; Kurz SC; Sulman EP; Placantonakis DG; Snuderl M; Chen W Elife; 2020 Sep; 9():. PubMed ID: 32909947 [TBL] [Abstract][Full Text] [Related]
26. An miR-340-5p-macrophage feedback loop modulates the progression and tumor microenvironment of glioblastoma multiforme. Liu Y; Li X; Zhang Y; Wang H; Rong X; Peng J; He L; Peng Y Oncogene; 2019 Dec; 38(49):7399-7415. PubMed ID: 31427735 [TBL] [Abstract][Full Text] [Related]
27. PD-L1 Expression and Combined Status of PD-L1/PD-1-Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients. Han J; Hong Y; Lee YS J Pathol Transl Med; 2017 Jan; 51(1):40-48. PubMed ID: 27989100 [TBL] [Abstract][Full Text] [Related]
28. MiR-181b modulates EGFR-dependent VCAM-1 expression and monocyte adhesion in glioblastoma. Liu YS; Lin HY; Lai SW; Huang CY; Huang BR; Chen PY; Wei KC; Lu DY Oncogene; 2017 Aug; 36(35):5006-5022. PubMed ID: 28459461 [TBL] [Abstract][Full Text] [Related]
29. EZH2 suppression in glioblastoma shifts microglia toward M1 phenotype in tumor microenvironment. Yin Y; Qiu S; Li X; Huang B; Xu Y; Peng Y J Neuroinflammation; 2017 Nov; 14(1):220. PubMed ID: 29132376 [TBL] [Abstract][Full Text] [Related]
31. Targeting the PD-1/PD-L1 pathway in glioblastoma multiforme: Preclinical evidence and clinical interventions. Maghrouni A; Givari M; Jalili-Nik M; Mollazadeh H; Bibak B; Sadeghi MM; Afshari AR; Johnston TP; Sahebkar A Int Immunopharmacol; 2021 Apr; 93():107403. PubMed ID: 33581502 [TBL] [Abstract][Full Text] [Related]
32. Anti-PD-L1 antibody direct activation of macrophages contributes to a radiation-induced abscopal response in glioblastoma. Ene CI; Kreuser SA; Jung M; Zhang H; Arora S; White Moyes K; Szulzewsky F; Barber J; Cimino PJ; Wirsching HG; Patel A; Kong P; Woodiwiss TR; Durfy SJ; Houghton AM; Pierce RH; Parney IF; Crane CA; Holland EC Neuro Oncol; 2020 May; 22(5):639-651. PubMed ID: 31793634 [TBL] [Abstract][Full Text] [Related]
33. Poly(I:C) primes primary human glioblastoma cells for an immune response invigorated by PD-L1 blockade. De Waele J; Marcq E; Van Audenaerde JR; Van Loenhout J; Deben C; Zwaenepoel K; Van de Kelft E; Van der Planken D; Menovsky T; Van den Bergh JM; Willemen Y; Pauwels P; Berneman ZN; Lardon F; Peeters M; Wouters A; Smits EL Oncoimmunology; 2018; 7(3):e1407899. PubMed ID: 29399410 [TBL] [Abstract][Full Text] [Related]
34. Targeting UDP-α-d-glucose 6-dehydrogenase alters the CNS tumor immune microenvironment and inhibits glioblastoma growth. Zhan D; Yalcin F; Ma D; Fu Y; Wei S; Lal B; Li Y; Dzaye O; Laterra J; Ying M; Lopez-Bertoni H; Xia S Genes Dis; 2022 May; 9(3):717-730. PubMed ID: 35782977 [TBL] [Abstract][Full Text] [Related]
35. Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma. Lee KS; Lee K; Yun S; Moon S; Park Y; Han JH; Kim CY; Lee HS; Choe G J Neurooncol; 2018 Feb; 136(3):453-461. PubMed ID: 29147863 [TBL] [Abstract][Full Text] [Related]
36. EGFRvIII-CAR-T Cells with PD-1 Knockout Have Improved Anti-Glioma Activity. Zhu H; You Y; Shen Z; Shi L Pathol Oncol Res; 2020 Oct; 26(4):2135-2141. PubMed ID: 31989402 [TBL] [Abstract][Full Text] [Related]
37. Temozolomide promotes immune escape of GBM cells via upregulating PD-L1. Wang S; Yao F; Lu X; Li Q; Su Z; Lee JH; Wang C; Du L Am J Cancer Res; 2019; 9(6):1161-1171. PubMed ID: 31285949 [TBL] [Abstract][Full Text] [Related]
38. Local Targeting of NAD Li M; Kirtane AR; Kiyokawa J; Nagashima H; Lopes A; Tirmizi ZA; Lee CK; Traverso G; Cahill DP; Wakimoto H Cancer Res; 2020 Nov; 80(22):5024-5034. PubMed ID: 32998997 [TBL] [Abstract][Full Text] [Related]
39. A Heterotypic Tridimensional Model to Study the Interaction of Macrophages and Glioblastoma In Vitro. Gattas MJ; Estecho IG; Lago Huvelle MA; Errasti AE; Carrera Silva EA; Simian M Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34065977 [TBL] [Abstract][Full Text] [Related]
40. Rapid visualization of PD-L1 expression level in glioblastoma immune microenvironment via machine learning cascade-based Raman histopathology. Zhou QQ; Guo J; Wang Z; Li J; Chen M; Xu Q; Zhu L; Xu Q; Wang Q; Pan H; Pan J; Zhu Y; Song M; Liu X; Wang J; Zhang Z; Zhang L; Wang Y; Cai H; Chen X; Lu G J Adv Res; 2023 Dec; ():. PubMed ID: 38072311 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]